FLT3 TriTAC

FLT3 TriTAC is a **preclinical T-cell engager biologic** from Harpoon Therapeutics built on the company's TriTAC platform. It is designed to bind **FMS-like tyrosine kinase 3** on target cells and engage **CD3-positive T cells**, thereby redirecting endogenous T cells to kill FLT3-expressing cells. Publicly available information indicates that this construct was used primarily as a **research-stage FLT3-targeted TriTAC molecule** in non-human primate studies evaluating Harpoon's **TriTAC-XR extended-release platform** intended to reduce cytokine release syndrome while preserving target-cell depletion; no distinct international nonproprietary name, brand name, or evidence of clinical-stage development has been identified.

Other names

FLT3 Tri-specific T cell Activating ConstructFLT-3 Tri-specific T cell Activating ConstructFLT 3 Tri-specific T cell Activating Construct